1 |
Gooi Z, Fakhry C, Goldenberg D, et al. AHNS Series: Do you know your guidelines?Principles of radiation therapy for head and neck cancer: A review of the National Comprehensive Cancer Network guidelines [J]. Head Neck, 2016, 38(7): 987.
|
2 |
Cooper JS, Porter K, Mallin K, et al. National Cancer Database report on cancer of the head and neck: 10-year update [J]. Head Neck, 2009, 31(6): 748.
|
3 |
Ye LL, Rao J, Fan XW, et al. Impact of tumor dimensions and lymph node density on the survival of patients with hypopharyngeal squamous cell carcinoma [J]. Cancer Manag Res, 2018, (10):4679.
|
4 |
Tian J, Liu X, Liu X, et al. Notch1 serves as a prognostic factor and regulates metastasis via regulating EGFR expression in hypopharyngeal squamous cell carcinoma [J]. Onco Targets Ther, 2018, (11):7395.
|
5 |
Han Y, Zhang M, Chen D, et al. Downregulation of RNA binding motif protein 17 expression inhibits proliferation of hypopharyngeal carcinoma FaDu cells [J]. Oncol Lett, 2018, 15(4): 5680.
|
6 |
Sepporta MV, Tumminello FM, Flandina C, et al. Follistatin as potential therapeutic target in prostate cancer [J]. Target Oncol, 2013, 8(4): 215.
|
7 |
Sugino K, Kurosawa N, Nakamura T, et al. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell [J]. J Biol Chem, 1993, 268(21): 15579.
|
8 |
Phillips DJ, DE Kretser DM. Follistatin: a multifunctional regulatory protein [J]. Front Neuroendocrinol, 1998, 19(4): 287.
|
9 |
Schneyer AL, Wang Q, Sidisy, et al. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay [J]. J Clin Endocrinol Metab, 2004, 89(10): 5067.
|
10 |
Thompson TB, Lerch TF, Cook RW, et al. The structure of the follistatin:activin complex reveals antagonism of both type I and type Ⅱ receptor binding [J]. Dev Cell, 2005, 9(4): 535.
|
11 |
Sebastiani G, Diaz M, Lopez-Bermejo A, et al. Circulating follistatin in the human foetus at term birth [J]. Pediatr Obes, 2012, 7(1): 39.
|
12 |
Kang W, Saqui-Salces M, Zavros Y, et al. Induction of follistatin precedes gastric transformation in gastrin deficient mice [J]. Biochem Biophys Res Commun, 2008, 376(3): 573.
|
13 |
Eichberger T, Sander V, Schnidar H, et al. Overlapping and distinct transcriptional regulator properties of the GLI1 and GLI2 oncogenes [J]. Genomics, 2006, 87(5): 616.
|
14 |
Harkonen P, Torn S, Kurkela R, et al. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state [J]. J Clin Endocrinol Metab, 2003, 88(2): 705.
|
15 |
Rossmanith W, Chabicovsky M, Grasl-Kraupp B, et al. Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control [J]. Mol Carcinog, 2002, 35(1): 1.
|
16 |
Van Schaik RH, Wierikx CD, Timmerman MA, et al. Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues [J]. Br J Cancer, 2000, 82(1): 112.
|
17 |
Di Simone N, Crowley WF, Wang QF, et al. Characterization of inhibin/activin subunit, follistatin, and activin type Ⅱ receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation [J]. Endocrinology, 1996, 137(2): 486.
|
18 |
Shikone T, Matzuk MM, Perlas E, et al. Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor [J]. Mol Endocrinol, 1994, 8(8): 983.
|
19 |
Seachrist DD, Sizemore ST, Johnson E, et al. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer [J]. Breast Cancer Res, 2017, 19(1): 66.
|
20 |
Zabkiewicz C, Resaul J, Hargest R, et al. Increased expression of follistatin in breast cancer reduces invasiveness and clinically correlates with better survival [J]. Cancer Genomics Proteomics, 2017, 14(4): 241.
|
21 |
Schneider CA, Rasband WS, Eliceiri KW. NIH image to imageJ: 25 years of image analysis [J]. Nat Methods, 2012, 9(7): 671.
|
22 |
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method [J]. Methods, 2001, 25(4): 402.
|
23 |
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 [J]. Nature, 1970, 227(5259): 680.
|
24 |
Liu N, Bi F, Pan Y, et al. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity [J]. Clin Cancer Res, 2004, 10(18Pt 1): 6239.
|
25 |
Welt CK, Lambert-Messerlian G, Zheng W, et al. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma [J]. J Clin Endocrinol Metab, 1997, 82(11): 3720.
|
26 |
Menon U, Riley SC, Thomas J, et al. Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma [J]. BJOG, 2000, 107(9): 1069.
|
27 |
Ren P, Chen FF, Liu HY, et al. High serum levels of follistatin in patients with ovarian cancer [J]. J Int Med Res, 2012, 40(3): 877.
|
28 |
Yuen MF, Norris S, Evans LW, et al. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis [J]. Scand J Gastroenterol, 2002, 37(2): 233.
|
29 |
Tomoda T, Nouso K, Miyahara K, et al. Prognotic impact of serum follistatin in patients with hepatocellular carcinoma [J]. J Gastroenterol Hepatol, 2013, 28(8): 1391.
|
30 |
Ogino H, Yano S, Kakiuchi S, et al. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice [J]. Clin Cancer Res, 2008, 14(3): 660.
|
31 |
Zhang P, Ruan Y, Xiao J, et al. Association of serum follistatin levels with histological types and progression of tumor in human lung cancer [J]. Cancer Cell Int, 2018, (18):162.
|
32 |
Tumminello FM, Badalamenti G, Fulfaro F, et al. Serum follistatin in patients with prostate cancer metastatic to the bone [J]. Clin Exp Metastasis, 2010, 27(8): 549.
|
33 |
Leto G, Incorvaia L, Flandina C, et al. Clinical impact of cystatin C/cathepsin L and follistatin/activin A systems in breast cancer progression: A preliminary report [J]. Cancer Invest, 2016, 34(9): 415.
|
34 |
Mange A, Dimitrakopoulos L, Soosaipillai A, et al. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma [J]. J Proteomics, 2016, 142:114.
|
35 |
Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer [J]. Br J Cancer, 2008, 98(3): 523.
|
36 |
Sritananuwat P, Sueangoen N, Thummarati P, et al. Blocking ERK1/2 signaling impairs TGF-beta1 tumor promoting function but enhances its tumor suppressing role in intrahepatic cholangiocarcinoma cells [J]. Cancer Cell Int, 2017, 17:85.
|
37 |
Cook SJ, Stuart K, Gilley R, et al. Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling [J]. FEBS J, 2017, 284(24): 4177.
|